Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma

被引:11
作者
Liu, Hangqi [1 ]
Zhang, Zhiwen [1 ]
Chen, Longyun [1 ]
Pang, Junyi [1 ]
Wu, Huanwen [1 ]
Liang, Zhiyong [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Mol Pathol Res Ctr, Dept Pathol,State Key Lab Complex Severe & Rare D, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
基金
中国国家自然科学基金;
关键词
ovarian clear cell carcinoma; homologous recombination repair gene; homologous recombination deficiency; molecular classification; next-generation sequencing; EXPRESSION; VARIANTS;
D O I
10.3389/fonc.2021.798173
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian clear cell carcinoma (OCCC) is aggressive and drug-resistant. The prevalence of homologous recombination repair (HRR) gene mutations and homologous recombination deficiency (HRD) remains largely unknown. It is also not clear whether the commonly used molecular-based classification for endometrial carcinoma (EC) is potentially applicable in OCCC. In this study, surgically resected samples were collected from 44 patients with OCCC. Genomic alterations were determined using next-generation sequencing. HRD was estimated by genomic instability. Of 44 patients with OCCC, two (4.5%) harbored likely pathogenic mutations in HRR genes. Notably, no pathogenic or likely pathogenic mutations were found in BRCA1/2. A total of 24 variants of uncertain significance (VUS) in HRR-related genes occurred in 18 (40.9%) patients. HRD was observed in only one case (2.3%). In addition, TP53 mutation and microsatellite instability-high (MSI-H) were identified in three patients (6.8%) and in one patient (2.3%), respectively. TP53 mutation was significantly associated with disease-free survival and overall survival. No POLE mutations were found. In conclusion, our results revealed a very low prevalence of HRR gene mutations and HRD in OCCC. Moreover, TP53 mutations and MSI-H are uncommon, while POLE mutations are extremely rare in OCCC. Our findings indicate that the evaluation of HRR gene mutations, HRD status, POLE mutations, and MSI-H may have limited clinical significance for OCCC treatment and prognostic stratification.
引用
收藏
页数:9
相关论文
共 35 条
  • [1] Ovarian Cancer, Version 2.2020
    Armstrong, Deborah K.
    Alvarez, Ronald D.
    Bakkum-Gamez, Jamie N.
    Barroilhet, Lisa
    Behbakht, Kian
    Berchuck, Andrew
    Chen, Lee-may
    Cristea, Mihaela
    DeRosa, Maria
    Eisenhauer, Eric L.
    Gershenson, David M.
    Gray, Heidi J.
    Grisham, Rachel
    Hakam, Ardeshir
    Jain, Angela
    Karam, Amer
    Konecny, Gottfried E.
    Leath, Charles A., III
    Liu, Joyce
    Mahdi, Haider
    Martin, Lainie
    Matei, Daniela
    McHale, Michael
    McLean, Karen
    Miller, David S.
    O'Malley, David M.
    Percac-Lima, Sanja
    Ratner, Elena
    Remmenga, Steven W.
    Vargas, Roberto
    Werner, Theresa L.
    Zsiros, Emese
    Burns, Jennifer L.
    Engh, Anita M.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (02): : 191 - +
  • [2] Integrated genomic analyses of ovarian carcinoma
    Bell, D.
    Berchuck, A.
    Birrer, M.
    Chien, J.
    Cramer, D. W.
    Dao, F.
    Dhir, R.
    DiSaia, P.
    Gabra, H.
    Glenn, P.
    Godwin, A. K.
    Gross, J.
    Hartmann, L.
    Huang, M.
    Huntsman, D. G.
    Iacocca, M.
    Imielinski, M.
    Kalloger, S.
    Karlan, B. Y.
    Levine, D. A.
    Mills, G. B.
    Morrison, C.
    Mutch, D.
    Olvera, N.
    Orsulic, S.
    Park, K.
    Petrelli, N.
    Rabeno, B.
    Rader, J. S.
    Sikic, B. I.
    Smith-McCune, K.
    Sood, A. K.
    Bowtell, D.
    Penny, R.
    Testa, J. R.
    Chang, K.
    Dinh, H. H.
    Drummond, J. A.
    Fowler, G.
    Gunaratne, P.
    Hawes, A. C.
    Kovar, C. L.
    Lewis, L. R.
    Morgan, M. B.
    Newsham, I. F.
    Santibanez, J.
    Reid, J. G.
    Trevino, L. R.
    Wu, Y. -Q.
    Wang, M.
    [J]. NATURE, 2011, 474 (7353) : 609 - 615
  • [3] Mismatch Repair Protein Expression in Clear Cell Carcinoma of the Ovary Incidence and Morphologic Associations in 109 Cases
    Bennett, Jennifer A.
    Morales-Oyarvide, Vicente
    Campbell, Sharon
    Longacre, Teri A.
    Oliva, Esther
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2016, 40 (05) : 656 - 663
  • [4] Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma
    Cai, KQ
    Albarracin, C
    Rosen, D
    Zhong, RS
    Zheng, WX
    Luthra, R
    Broaddus, R
    Liu, JS
    [J]. HUMAN PATHOLOGY, 2004, 35 (05) : 552 - 559
  • [5] Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma
    Chao, Angel
    Lai, Chyong-Huey
    Wang, Tzu-Hao
    Jung, Shih-Ming
    Lee, Yun-Shien
    Chang, Wei-Yang
    Yang, Lan-Yang
    Ku, Fei-Chun
    Huang, Huei-Jean
    Chao, An-Shine
    Wang, Chin-Jung
    Chang, Ting-Chang
    Wu, Ren-Chin
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2018, 96 (06): : 527 - 536
  • [6] Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2, and RAD51C Status
    Cunningham, J. M.
    Cicek, M. S.
    Larson, N. B.
    Davila, J.
    Wang, C.
    Larson, M. C.
    Song, H.
    Dicks, E. M.
    Harrington, P.
    Wick, M.
    Winterhoff, B. J.
    Hamidi, H.
    Konecny, G. E.
    Chien, J.
    Bibikova, M.
    Fan, J. -B.
    Kalli, K. R.
    Lindor, N. M.
    Fridley, B. L.
    Pharoah, P. P. D.
    Goode, E. L.
    [J]. SCIENTIFIC REPORTS, 2014, 4
  • [7] BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance
    Eccles, D. M.
    Mitchell, G.
    Monteiro, A. N. A.
    Schmutzler, R.
    Couch, F. J.
    Spurdle, A. B.
    Gomez-Garcia, E. B.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (10) : 2057 - 2065
  • [8] Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies
    Erickson, Britt K.
    Zeybek, Burak
    Santin, Alessandro D.
    Fader, Amanda N.
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2020, 32 (01) : 57 - 64
  • [9] Clear-cell carcinoma of the ovary
    Fujiwara, K.
    Shintani, D.
    Nishikawa, T.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : 50 - 52
  • [10] Integrated genomic characterization of endometrial carcinoma
    Getz, Gad
    Gabriel, Stacey B.
    Cibulskis, Kristian
    Lander, Eric
    Sivachenko, Andrey
    Sougnez, Carrie
    Lawrence, Mike
    Kandoth, Cyriac
    Dooling, David
    Fulton, Robert
    Fulton, Lucinda
    Kalicki-Veizer, Joelle
    McLellan, Michael D.
    O'Laughlin, Michelle
    Schmidt, Heather
    Wilson, Richard K.
    Ye, Kai
    Ding, Li
    Mardis, Elaine R.
    Ally, Adrian
    Balasundaram, Miruna
    Birol, Inanc
    Butterfield, Yaron S. N.
    Carlsen, Rebecca
    Carter, Candace
    Chu, Andy
    Chuah, Eric
    Chun, Hye-Jung E.
    Dhalla, Noreen
    Guin, Ranabir
    Hirst, Carrie
    Holt, Robert A.
    Jones, Steven J. M.
    Lee, Darlene
    Li, Haiyan I.
    Marra, Marco A.
    Mayo, Michael
    Moore, Richard A.
    Mungall, Andrew J.
    Plettner, Patrick
    Schein, Jacqueline E.
    Sipahimalani, Payal
    Tam, Angela
    Varhol, Richard J.
    Robertson, A. Gordon
    Pashtan, Itai
    Saksena, Gordon
    Onofrio, Robert C.
    Schumacher, Steven E.
    Tabak, Barbara
    [J]. NATURE, 2013, 497 (7447) : 67 - 73